IceCure Medical (NASDAQ:ICCM) Price Target Cut to $2.50 by Analysts at HC Wainwright

IceCure Medical (NASDAQ:ICCM) had its target price reduced by HC Wainwright from $3.00 to $2.50 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for IceCure Medical’s FY2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.25) EPS.

IceCure Medical Price Performance

Shares of ICCM stock opened at $0.72 on Wednesday. IceCure Medical has a 12-month low of $0.52 and a 12-month high of $1.57. The firm has a market capitalization of $32.73 million, a price-to-earnings ratio of -2.17 and a beta of 0.57. The company has a quick ratio of 2.88, a current ratio of 3.39 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average of $0.72 and a 200-day moving average of $1.02.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the previous year, the business earned ($0.09) EPS. On average, equities research analysts forecast that IceCure Medical will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC purchased a new stake in IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical as of its most recent SEC filing. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.